Biogen Rallies On Tecfidera Patent Decision

Biogen Inc BIIB shares were trading higher Wednesday following the issuing of a decision by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board on a patent trial challenge by Mylan NV MYL on '514 Tecfidera that was in Biogen's favor.

See Also: 9 Takeaways From The JPMorgan Healthcare Conference

Biogen’s top product is a multiple sclerosis drug, Tecfidera. Mylan had asked the U.S. Patent and Trademark Office to take a look at Biogen’s exclusive hold on Tecfidera until 2028, according to Barron’s.

Biogen shares were trading 24.62% higher at $353.04 at the time of publication, while Mylan shares were up 2.49% at $22.82.